Cardio3 BioSciences

General Info

Instrument Name
IPO Type
Initial Public Offering
IPO Date
Brussels Paris

Background Info

Price Range
EUR 16.65 - 19.00

Cardio3 BioSciences is a biotechnology company specializing in research and development for regenerative, protective, and reconstructive therapies for treating cardiac disorders (primarily heart failure and myocardial infarction).

Source: Cofisem

Operation Calendar

Subscription period :
From 21/06/2013 up to 03/07/2013 à 16h (Brussels and Paris time)

Centralisation date :

Pricing date / Annoucement of the IPO result :
04/07/2013 / A Euronext market notice will be issued on 04/07/2013

First trading date :
The trading will start on 05/07/2013 on an "As-if-andwhen- issued basis" under the product name "CARDIO3 PROMESSES". The trading of ordinary shares will start on 10/07/2013 under the product name "CARDIO3 BIO" (ISIN code and the trading symbol will remain the same).

IPO Financial Info

No of shares made public

Number of securities to be listed: 6,044,067 (excluding the exercise of the Extension Op tion and the Over-allotement Option)

Capital Raised

Personnel Info

Company Website



The above information is for informational purposes only without regard to any particular user’s investment objectives, financial situation or means. Accordingly, it is not directed at or intended for publication or distribution to any person in any jurisdiction where doing so would result in contravention of any applicable laws or regulations. In particular, the securities above mentioned may be subject to selling restrictions in certain jurisdictions. Therefore, please note that information contained in the offering document(s) associated to the products or investments described therein may be addressed to and/or targeted at persons who are residents of particular countries or states only, as further described in the offering document(s).

In this context:

i)                    all the persons using this service should inform themselves about and comply with any such restrictions.Any failure to comply with those restrictions may constitute a violation of the securities law of any such jurisdictions.

ii)                   information contained in the offering document(s) is not intended for use, and it should not be relied upon, by any person outside the particular countries or states, as further described in the offering document(s), and/or to whom any offer contained in the offering document(s) is not addressed.

In particular, unless this document specifically states otherwise, the securities mentioned therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and, if not so registered, may not be offered or sold within the United States except in certain transactions exempt from, or not subject to, the registration requirements of the Securities Act.

Prior to relying on the information contained in any associated offering document(s), it is the responsibility of the individual user to consider his or her legal and regulatory position in the relevant jurisdiction (in particular whether or not he or she is part of the intended addressees), the risks associated with trading such securities or investments and to ensure that the use of the information available and the subsequent making of any investment does not contravene any such restrictions or applicable laws and regulations of any jurisdiction. Potential users of products or investments described above (including those wishing to trade them or to offer and sell them to others) should familiarize themselves with the full contract specification of the security or investment concerned and any associated information, such as any applicable legal or regulatory provisions. Please seek the advice of professionals, as appropriate, regarding the evaluation of any specific security, investment, index, report, opinion, advice or other content.